<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004808'>Acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is frequently encountered in elderly patients (&gt; 65) whereas most myelosuppressive chemotherapy protocols are restricted to younger patients </plain></SENT>
<SENT sid="1" pm="."><plain>We retrospectively reviewed the 21 patients older than 65 (median age: 70, range: 66-86) hospitalized in our <z:hpo ids='HP_0001909'>leukemia</z:hpo> unit for recently diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> between 1 </plain></SENT>
<SENT sid="2" pm="."><plain>1 </plain></SENT>
<SENT sid="3" pm="."><plain>1988 and 31 </plain></SENT>
<SENT sid="4" pm="."><plain>3 </plain></SENT>
<SENT sid="5" pm="."><plain>1993 </plain></SENT>
<SENT sid="6" pm="."><plain>16 had de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 5 had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> secondary to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>Induction therapy consisted of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and either daunorubicine or <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> at conventional dosage in 18/21 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Early consolidation therapy was given to 14/21 patients and consisted of m-AMSA and <z:chebi fb="0" ids="4911">VP-16</z:chebi> in 11 of them </plain></SENT>
<SENT sid="9" pm="."><plain>The response to, and toxicity from, myelosuppressive chemotherapy was different according to the type of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In patients with n-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> a complete remission (CR) was obtained in 63% (10/16) and only 19% (3/16) died of MCT-related toxicity </plain></SENT>
<SENT sid="11" pm="."><plain>In contrast, only 1/5 patients with s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> achieved CR while 4/5 died of toxicity </plain></SENT>
<SENT sid="12" pm="."><plain>The median duration of CR was 40 weeks (range: 5-147+) and median overall survival 23 weeks (range: 1-211+), with an estimated 3-year overall survival rate of 9.5% (2/21) </plain></SENT>
<SENT sid="13" pm="."><plain>Overall survival of patients with n-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was significantly longer than that of patients with s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (p &lt; 0.05) </plain></SENT>
<SENT sid="14" pm="."><plain>Hospital stay in relation to survival time was 100% for patients with s-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 49% for patients with n-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> not achieving CR and 25% for patients with n-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with CR </plain></SENT>
<SENT sid="15" pm="."><plain>In conclusion, elderly patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> can benefit from myelosuppressive chemotherapy providing they present with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>